US OptionsDetailed Quotes
RLAY241220P7500
- 2.00
- 0.000.00%
15min DelayClose Nov 27 16:00 ET
0.00High0.00Low
2.00Open2.00Pre Close0 Volume61 Open Interest7.50Strike Price0.00Turnover114.28%IV-14.58%PremiumDec 20, 2024Expiry Date2.70Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9330Delta0.1096Gamma1.76Leverage Ratio-0.0034Theta-0.0025Rho-1.64Eff Leverage0.0015Vega
Relay Therapeutics Stock Discussion
Sign in to post a comment
Columns Options Market Statistics: Options Popped as Investors Placed Bets Before Nike Revealed Earnings
News Highlights
$Meta Platforms (META.US)$ shares increased 0.70%, with with option volume of 0.37 million, and calls accounted for 58.2% of the volume. The $585 calls expiring October 4 were traded most actively.
Meta Platforms said on Tuesday that the company will expand artificial intelligence investment in Vietnam, including production of its mixed reality Quest 3S headsets in the country from next...
$Meta Platforms (META.US)$ shares increased 0.70%, with with option volume of 0.37 million, and calls accounted for 58.2% of the volume. The $585 calls expiring October 4 were traded most actively.
Meta Platforms said on Tuesday that the company will expand artificial intelligence investment in Vietnam, including production of its mixed reality Quest 3S headsets in the country from next...
39
2
$Relay Therapeutics (RLAY.US)$ Did they just pump and dump?
$Relay Therapeutics (RLAY.US)$ CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.(NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an add...
2
6
$Relay Therapeutics (RLAY.US)$ Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
3 MINUTES AGO, 6:55 AM EDT
VIA GLOBENEWSWIRE
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D
Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse...
3 MINUTES AGO, 6:55 AM EDT
VIA GLOBENEWSWIRE
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D
Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse...
3
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Relay Therapeutics (RLAY.US)$
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Relay Therapeutics announced positive interim data for RLY-2608, a pan-mutant and isoform-selective inhibitor of PI3Kα, in treating PI3Kα-mutated, HR+/HER2- metastatic breast cancer. Key findings include:
- 9.2-month median progression-free survival (PFS) in heavily pre-treated patients at the recommended Phase 2 dose (RP2D)
- 33% overal...
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Relay Therapeutics announced positive interim data for RLY-2608, a pan-mutant and isoform-selective inhibitor of PI3Kα, in treating PI3Kα-mutated, HR+/HER2- metastatic breast cancer. Key findings include:
- 9.2-month median progression-free survival (PFS) in heavily pre-treated patients at the recommended Phase 2 dose (RP2D)
- 33% overal...
$Schrodinger (SDGR.US)$ i have been saying this for days and weeks now but if you're looking for a time to buy small caps now is the time it's still not too late these small caps have massive price gaps they need to fill they'll be forming giant cup and handles and many of them have been bottoming for the longest time while the mag7 were carrying the whole SPY & QQQ
they just needed a catalyst from rate cuts and this expectation is enough to tr...
they just needed a catalyst from rate cuts and this expectation is enough to tr...
7
$Relay Therapeutics (RLAY.US)$ period of consolidation is looking solid.
rate cut by fed is needed as a key catalyst
rate cut by fed is needed as a key catalyst
1
1
No comment yet
54088 FROM MBS : 3299
103356238jenny tan :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")